No CrossRef data available.
Article contents
AIDS and Antiretroviral Drugs in South Africa: Public Health, Politics, and Individual Suffering: A Review of Brian Tilley's It's My Life
Published online by Cambridge University Press: 01 January 2021
Extract
The word “epidemic” seems inadequate to describe the spread of the HIV virus in sub-Saharan Africa. The latest estimates suggest that 28.5 million people in this region are infected, including 5 million in South Africa alone. The HIV and AIDS pandemic, with infection rates of over 20 percent in seven African countries, rivals the worst of history's disease outbreaks, including the bubonic plague of medieval times. The devastating effects of the disease on the continent are compounded by extreme poverty in the region and the lack of medical infrastructure essential for delivering the full range of available treatments for HIV infection, AIDS, and the opportunistic infections associated with the disease. Of the 40 million people infected with HIV worldwide, only 730,000 receive combination antiretroviral therapies. In the entire African continent, only 30,000 infected people currently receive such forms of treatment.
- Type
- Article
- Information
- Copyright
- Copyright © American Society of Law, Medicine and Ethics 2003
References
See It's My Life, produced by B. Tilley and First Run/Icarus Films, 72 minutes (2001), videocassette (explaining that 4.7 million South Africans are infected with HIV or have AIDS). See also Joint United Nations Programme on HIV/AIDS (UNAIDS), “Table of Country Specific HIV/AIDS Estimates and Data, End 2001,” Report on the Global HIV/AIDS Epidemic 2002 (July 2002), available at <http://www.unaids.org/epidemic_update/reportjuly02/english/table.html> (providing current statistics on the worldwide rate of HIV infection and AIDS, including an estimate of 950,000 infected in North America). (providing current statistics on the worldwide rate of HIV infection and AIDS, including an estimate of 950,000 infected in North America).' href=https://scholar.google.com/scholar?q=See+It's+My+Life,+produced+by+B.+Tilley+and+First+Run/Icarus+Films,+72+minutes+(2001),+videocassette+(explaining+that+4.7+million+South+Africans+are+infected+with+HIV+or+have+AIDS).+See+also+Joint+United+Nations+Programme+on+HIV/AIDS+(UNAIDS),+“Table+of+Country+Specific+HIV/AIDS+Estimates+and+Data,+End+2001,”+Report+on+the+Global+HIV/AIDS+Epidemic+2002+(July+2002),+available+at++(providing+current+statistics+on+the+worldwide+rate+of+HIV+infection+and+AIDS,+including+an+estimate+of+950,000+infected+in+North+America).>Google Scholar
See Stephenson, J., “Apocalypse Now: HIV/AIDS in Africa Exceeds the Experts’ Worst Predictions,” JAMA, 284 (2000): 556–57 (noting that the epidemic in South Africa, Botswana, and Zimbabwe is so widespread that these countries will experience negative population growth by 2003, and that five other sub-Saharan African countries are expected to experience a population growth of nearly zero). See also Foster, G., “Supporting Community Efforts to Assist Orphans in Africa,” N. Engl. J. Med., 346 (2002): 1907–10 (providing additional statistics); Stephenson, J., “AIDS in South Africa Takes Center Stage,” JAMA, 284 (2000): 165–67.CrossRefGoogle Scholar
See Brown, D., “Conferees Call for New AIDS Alliance,” Washington Post, July 7, 2002, at A13. See also Steinbrook, R., “Beyond Barcelona — The Global Response to HIV,” N. Engl. J. Med., 347 (2002): 553–54 (noting that AIDS has also orphaned 11 million children in sub-Saharan Africa).Google Scholar
See It's My Life, supra note 1.Google Scholar
At one point in the film, Achmat explains that the “majority of people with HIV don’t have a face,… they’re desperate, poor, alone. But me personally with HIV as someone who could access medicines — I can’t look them in the eye,…. I can’t lead them when I know they’re going to die and they can't get medicines. I want the right to life for myself … but in a political community where that right is extended to everyone.” See It's My Life, supra note 1. See also Achmat, Z., “Commentary: Most South Africans Cannot Afford Anti-HIV Drugs,” British Medical Journal, 324 (2002): 217–18.Google Scholar
See Gathii, J.T., “Rights, Patents, Markets and the Global AIDS Pandemic,” Florida Journal of International Law, 14 (2002): 261–352 (explaining that these drug regimens have reduced the mortality rates from AIDS by 75 percent in the United States). See also Voelker, R., “Setting Priorities and Budgets to Fight Against Global AIDS,” JAMA, 284 (2000): 2709–10 (explaining that providing highly active antiretroviral therapy (HAART) in many African countries would consume anywhere from half to up to 57 times the health care budget in the affected countries).Google Scholar
See Gathii, supra note 6, at 271.Google Scholar
See Bombach, K.M., Note, “Can South Africa Fight AIDS? Reconciling the South African Medicines and Related Substances Act with the TRIPS Agreement,” Boston University International Law Journal, 19 (2001): 273–306 (describing the Medicines and Related Substances Act of 1997).Google Scholar
See DeYoung, K., “Makers of AIDS Drugs Drop S. Africa Suit,” Washington Post, April 19, 2001, at A13; Swarns, R.L., “Drug Makers Drop South Africa Suit Over AIDS Medicine,” New York Times, April 20, 2001, at A1.Google Scholar
See It's My Life, supra note 1.Google Scholar
See, e.g., Attaran, A. and Gillespie-White, L., “Do Patents for Antiretroviral Drugs Constrain Access to AIDS Treatment in Africa?,” JAMA, 286 (2001): 1886–92 (concluding that “a variety of de facto barriers are more responsible for impeding access to antiretroviral treatment, including but not limited to the poverty of African countries, [and] the high cost of antiretroviral treatment”); Gathii, J.T., “Construing Intellectual Property Rights and Competition Policy Consistently with Facilitating Access to Affordable AIDS Drugs to Low-End Consumers,” Florida Law Review, 53 (2001): 727–88; Scherer, F.M., “The Pharmaceutical Industry and World Intellectual Property Standards,” Vanderbilt Law Review, 53 (2000): 2245–54; Sykes, A.O., “TRIPS, Pharmaceuticals, Developing Countries, and the Doha ‘Solution,’” Chicago Journal of International Law, 3 (2002): 47–68; Bass, N.A., Note, “Implications of the TRIPS Agreement for Developing Countries: Pharmaceutical Patent Laws in Brazil and South Africa in the 21st Century,” George Washington International Law Review, 34 (2002): 191–222; Patrick, M., Note, “Compulsory Licensing and the South African Medicine Act of 1997,” New York Law School Scholarly Journal of International & Comparative Law, 21 (2001): 109–25.Google Scholar
See Editorial, “AIDS Realism in Africa,” Boston Globe, April 26, 2002, at A18 (describing Mbeki's original position and his later decision to acknowledge that HIV causes AIDS); Block, R., “South Africa's Mbeki Puts Personal Stamp on New AIDS Policy,” Wall Street Journal, April 25, 2002, at A16 (same). Early in the AIDS epidemic in the United States, some controversy arose over the Centers for Disease Control's case definition. See Noah, L., “Pigeonholing Illness: Medical Diagnosis as a Legal Construct,” Hastings Law Journal, 50 (1999): 241–307, at 291–92.Google Scholar
For example, one prevalent myth suggests that sexual intercourse with a virgin child will provide protection against HIV infection. See Swarns, R.L., “Grappling with South Africa's Alarming Increase in the Rapes of Children,” New York limes, January 29, 2002, at A6.Google Scholar
See Stephenson, , “AIDS in South Africa Takes Center Stage,” supra note 2, at 166.Google Scholar
See Shaywitz, D.A. and Ausiello, D.A., “Improved Drug Regimens Help Patients Take Their Medicine,” New York Times, July 16, 2002, at F5 (explaining that taking the medicine incorrectly just 6 percent of the time reduces by half the chance of successfully restraining viral growth, and discussing efforts to develop simpler HIV drug regimens).Google Scholar
For a discussion of problems with drug therapy implementation due to inadequate health infrastructure, see Farmer, P. et al., “Community-Based Approaches to HIV Treatment in Resource-Poor Settings,” Lancet, 358 (2001): 404–09 (acknowledging the problem, but suggesting that “minor modifications could improve local capacity to care for those sick with advanced HIV disease.”).CrossRefGoogle Scholar
See Stephenson, J., “Cheaper HIV Drugs for Poor Nations Bring a New Challenge: Monitoring Treatment,” JAMA, 288 (2002): 151–53.Google Scholar
See id. (explaining that the flow cytometer required to monitor CD4 T-cell counts costs about $100,000, plus the cost of reagents, training, and staffing).Google Scholar
See Yeni, P.G. et al., “Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society-USA Panel,” JAMA, 288 (2002): 222–35.Google Scholar
See Grady, D., “Generic Medicine for AIDS Raises New Set of Concerns,” New York Times, April 24, 2001, at Dl. See also Noah, L., “NAFTA's Impact on the Trade in Pharmaceuticals,” Houston Law Review, 33 (1997): 1293–326, at 1313–14 (summarizing public health concerns associated with drugs sold in Mexico).Google Scholar
Most of the 590,000 infants infected with HIV from their mothers live in developing countries. See DeCock, K.M. et al., “Prevention of Mother-to-Child HIV Transmission in Resource-Poor Countries: Translating Research into Policy and Practice,” JAMA, 283 (2000): 1175–82. See also Mitka, M., “MTCT-Plus Program Has Two Goals: End Maternal HIV Transmission and Treat Mothers,” JAMA, 288 (2002): 153–54.CrossRefGoogle Scholar
See DeCock, et al., supra note 21 (discussing strategies to reduce transmission during the intrapartum and postpartum periods using short course antiretroviral treatments and emphasizing the importance of primary prevention strategies to accompany these efforts).Google Scholar
See, e.g., Wood, E. et al., “Extent to Which Low-Level Use of Anti-Retroviral Treatment Could Curb the AIDS Epidemic in Sub-Saharan Africa,” Lancet, 355 (2000): 2095–100.CrossRefGoogle Scholar
See Trachtenberg, J.D. and Sande, M.A., “Emerging Resistance to Nonnucleoside Reverse Transcriptase Inhibitors: A Warning and a Challenge,” JAMA, 288 (2002): 239–41. See also Hirsch, M.S., “HIV Drug Resistance — A Chink in the Armor,” N. Engl. J. Med., 347 (2002): 438–39.CrossRefGoogle Scholar
See Trachtenberg and Sande, supra note 24.Google Scholar
See id. at 240 (“The struggling nations of sub-Saharan Africa … are desperate for immediate action to control the HIV epidemic… The time to introduce [antiretroviral therapy] is now. The issues to be addressed are how to use [the therapy] and whether [it] will be reliably available to everyone.”).Google Scholar
See Harries, A.D. et al., “Preventing Antiretroviral Anarchy in Sub-Saharan Africa,” Lancet, 358 (2001): 410–14, at 410. For a discussion of similar concerns in the context of antibiotic resistance, see Noah, L., “Challenges in the Federal Regulation of Pain Management Technologies,” Journal of Law, Medicine & Ethics, 31, no. 1 (2003): 55–74.CrossRefGoogle Scholar
See Harries, A.D. et al., supra note 27, at 411–12 (advocating that the program be integrated with systematic tuberculosis control in order to provide maximum benefit). Infectious disease experts are working to develop workable models to provide complex medical care in resource-poor environments. See, e.g., Mitnick, C. et al., “Community-Based Therapy for Multidrug-Resistant Tuberculosis in Lima, Peru,” N. Engl. J. Med., 348 (2003): 119–28.Google Scholar
See Nicoll, A. and Hamer, F.F., “Are Trends in HIV, Gonorrhoea, and Syphilis Worsening in Western Europe?,” British Medical Journal, 324 (2002): 1324–27 (noting that, since 1995, new cases of sexually transmitted HIV increased by 20 percent in a group of western European countries, which suggests that people may not be modifying their sexual behavior in response to the risk of infection).CrossRefGoogle Scholar
See Marseille, E., Hofmann, P.B., and Kahn, J.G., “HIV Prevention Before HAART in Sub-Saharan Africa,” Lancet, 359 (2002): 1851–56 (comparing the costs and benefits of HIV prevention efforts to the costs and benefits of antiretroviral therapy in existing AIDS cases and advocating that funds be directed primarily to prevention for as long as resources remain limited).CrossRefGoogle Scholar
See Satcher, D., “Global HIV/AIDS Revisited,” JAMA, 286 (2001): 2535. See also Farmer et al., supra note 16, at 408 (arguing that AIDS prevention alone is insufficient and explaining that, because antiretroviral therapy reduces viral load, it may reduce rates of transmission and therefore serve a preventive function).Google Scholar
See Banta, D., “Worldwide Interest in Global Access to Drugs,” JAMA 285 (2001): 2844–46; Banta, D., “Increase in Global Access to Essential Drugs Sought,” JAMA, 283 (2000): 321–23.CrossRefGoogle Scholar
See Brown, supra note 3.Google Scholar
See Satcher, supra note 31 (describing the new Global Fund to Fight Infectious Diseases HIV/AIDS, Tuberculosis, and Malaria). See also Brown, supra note 3 (describing a proposal that would provide health care expertise in developing countries to assist in the delivery of AIDS therapies).Google Scholar
See Brown, supra note 3.Google Scholar
See Exec. Order No. 13,155,65 Fed. Reg. 30,521 (2000). See also McNeil, D.G. Jr., “Bush Keeps Clinton Policy on Poor Lands’ Need for AIDS Drugs,” New York Times, February 22, 2001, at A9. Critics are quick to point out that low income, uninsured people in the United States also find it difficult to access the more expensive antiretroviral therapies and suggest that the United States ought not to leave its own citizens behind as it assists poor persons overseas. See Abelson, R., “Glaxo Freezes Prices of AIDS Drugs in U.S.,” New York Times, June 21, 2002, at C12.Google Scholar
See Dugger, C.W., “A Catch-22 on Drugs for the World's Poor,” New York Times, November 16, 2001, at W1; Winestock, G. and Cooper, H., “Activists Outmaneuver Drug Makers at WTO,” Wall Street Journal, November 14, 2001, at A2.Google Scholar
See, e.g., Alexander, B.C., “Lack of Access to HIV/AIDS Drugs in Developing Countries: Is There a Violation of the International Human Right to Health?,” Human Rights Brief, 8 (2001): 12–14; Gathii, , supra note 6, at 272–78; Gostin, L. and Mann, J., “Toward the Development of a Human Rights Impact Assessment for the Formulation and Evaluation of Public Health Policies,” in Mann, J. et al., eds., Health and Human Rights: A Reader (New York: Routledge, 1999): 54–71.Google Scholar
Cf. Woolf, S.H., “The Need for Perspective in Evidence-Based Medicine,” JAMA, 282 (1999): 2358–65. See generally Noah, L. and Noah, B., Law, Medicine, and Medical Technology: Cases and Materials (New York: Foundation Press, 2002).CrossRefGoogle Scholar